U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of ...
Pfizer's BRAFTOVI® (encorafenib) in combo with cetuximab and mFOLFOX6 approved by FDA for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation, based on 61% overall response rate in Phase 3 BREAKWATER trial.
Highlighted Terms
Related News
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of ...
Pfizer's BRAFTOVI® (encorafenib) in combo with cetuximab and mFOLFOX6 approved by FDA for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation, based on 61% overall response rate in Phase 3 BREAKWATER trial.